We used X-ray crystallography to solve the complete apo structures of human and avian FluPol A at a resolution of 3.32 Å and 3.63 Å, respectively (Fig. 1a, Extended Data Fig. 1a-f 1 2 S e P t e M B e r 2 0 1 9 | V O L 5 7 3 | N A t U r e | 2 8 7
Letter reSeArCH Supplementary Fig. 1 ). The structures of human and avian FluPol A are essentially identical, and form dimers of heterotrimers with dimerization mediated by the C-terminal domain of the PA subunit, the thumb subdomain of PB1 and the N1 subdomain of PB2 (Fig. 1a, b , Extended Data Fig. 1g-i) . A key feature of this dimer interface is loop 352-356 in the C-terminal domain of PA, which interacts with the same loop of the second polymerase (Fig. 1c, Extended Data Fig. 1g ). The dimer interface also involves hydrogen bonds between the C-terminal domain of PA and N1 subdomain of PB2 (Fig. 1d, Extended Data Fig. 1h ). The mutation PA(E352A/K353A/I354A/P355A/R356A) (hereafter, PA(352-356A)) resulted in a shift towards a monomeric FluPol A heterotrimer (Extended Data Fig. 2a ). FluPol A dimerization through the same interface was also observed in mammalian cells (Extended Data Fig. 2b ), and has been observed in previous studies 11 of a truncated avian FluPol A . To assess the importance of dimerization for FluPol A function, we used a mini-replicon assay to measure viral transcription and replication in the context of viral ribonucleoprotein complexes (RNPs) (Fig. 2a) . The PA(352-356A) mutation of the dimer interface, and mutations designed to destabilize the PB2 loop 71-76 and PA loop 352-356 at the dimer interface, significantly decreased the synthesis of all viral RNAs (Fig. 2b, Extended Data Fig. 2c ). Co-expression of PA(352-356A) with PA(D108A)-a polymerase that is transcriptiondeficient but replication-competent 12, 13 -led to a significant increase in mRNA signal, which indicates that the PA(352-356A) mutant is specifically deficient in viral genome replication (Fig. 2b) . Consistent with this, the PA(352-356A) mutation did not inhibit transcription in vitro, using a vRNA template and capped RNA primer (Fig. 2c) . The mutation also did not affect primer-independent synthesis of cRNA on a vRNA template, but the mutant was deficient in vRNA synthesis on a cRNA template (Fig. 2d , e) that involves synthesis of pppApG at positions 4 and 5, and subsequent realignment of the template 14 . In ApG dinucleotide-primed assays, the PA(352-356A) mutant showed activity on both vRNA and cRNA templates, but on the cRNA template it promoted the formation of a short, 12-nucleotide product and other incorrectly initiated products (Extended Data Fig. 2d, e) . The ratio of the full-length, 15-nucleotide product to the short, 12-nucleotide product was dependent on the concentration of FluPol A and could be increased by adding a polymerase active-site mutant (PB1a), which suggested the involvement of an intermolecular interaction between polymerases (Extended Data Fig. 2f, g ). These data show that the interface of the FluPol A dimer is important for the initiation of vRNA synthesis on the cRNA template, and suggest that dimerization promotes stabilization of the replication complex and the correct positioning of the cRNA template to enable terminal, pppApG-primed initiation during synthesis of vRNA.
To investigate the binding of FluPol A to the cRNA template, we determined the structure of dimeric FluPol A in the presence of a cRNA 
2.0 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0028 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 0.0395 P = 0.0492 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0564 Letter reSeArCH promoter (comprising the 5′ and 3′ termini of cRNAs) 3,4 at a resolution of 4.07 Å using cryo-electron microscopy (cryo-EM) (Fig. 3a , Extended Data Fig. 3a -f, Extended Data Table 2 ). Although the endonuclease domain of PA and C-terminal domains of PB2 could not be resolved (consistent with previous observations that these domains are flexible [15] [16] [17] ), unambiguous density was observed for the dimer interface; this revealed a dimer interface that was essentially identical to that in the FluPol A crystal structures (Fig. 1a) . Only the 5′ cRNA was clearly resolved in the density maps, and showed a hook structure that was bound in a pocket formed by PA and PB1, as has previously been observed in structures of influenza polymerases with 5′ vRNA and cRNA 6, 16, 18 . Unresolved density around the template entry channel was observed, suggesting that the 3′ cRNA has entered the active site but is highly dynamic (Extended Data Fig. 3g, h ). These results confirm that cRNA-bound FluPol A can form dimers in solution.
To gain further insight into FluPol A dimerization and cRNA binding, we used a nanobody (Nb8205) raised against FluPol A that reduces FluPol A dimerization (Extended Data Fig. 4a-c) . A crystal structure of the apo FluPol A -Nb8205 complex solved at a resolution of 3.34 Å revealed that the complementarity determining regions of Nb8205 interact with FluPol A at the C-terminal domain of PA and thumb subdomain of PB1, a site that is close to the dimer interface (Extended Data Fig. 4d , e, Extended Data Table 1 ). We also used cryo-EM to solve the structures of monomeric and dimeric FluPol A bound to Nb8205 and cRNA promoter at resolutions of 3.79 Å and 4.15 Å, respectively (Fig. 3b, Extended Data Fig. 5a -h, Extended Data Table 2 ). The structure of the Nb8205-bound FluPol A dimer is essentially identical to the dimer that is observed in the absence of Nb8205: these dimers show the same binding mode for the 5′ cRNA, and unresolved density around the template entry channel suggests the presence of a dynamic 3′ cRNA in the active site (Extended Data Fig. 5i ). By contrast, the structure of the Nb8205-bound FluPol A monomer revealed binding of both 5′ and 3′ cRNA (Fig. 3b, Supplementary Video 1) . The 5′ cRNA is bound in the hook conformation (as observed in the FluPol A dimer), whereas the 3′ cRNA occupies a binding site that is formed between the C-terminal domain of PA, the thumb subdomain of PB1 and the N1 subdomain of PB2. Only bases 4 to 8 of the 15-nucleotide-long 3′ cRNA could be resolved; these bases are coordinated by the residues of PB1 loop 553-571 as well as a series of charged residues of PA (E300, Y464, K488 and R496) (Fig. 3c, Supplementary Video 1) . We observed the same binding site for the 3′ cRNA in a cryo-EM structure of the monomeric form of influenza B virus polymerase (FluPol B ) (Extended Data Fig. 6a-f ). This 3′ cRNA binding site lies close to the interface of the FluPol A dimer (Extended Data Fig. 6g) , and could represent a docking site for the 3′ cRNA in the replication pre-initiation state of FluPol A . The binding site could also accommodate the 3′ cRNA during replication elongation, after the 3′ cRNA is copied and extruded through the template exit channel. This site is distinct from the previously observed 3′ vRNA binding site in structures of bat FluPol A and human FluPol B , but lies in a position similar to that of the binding site of 3′ vRNA of the RNA polymerase of La Crosse orthobunyavirus 6, 18, 19 (Extended Data Fig. 6h) . 
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Comparing the monomeric and dimeric FluPol A structures in complex with Nb8205 revealed that dimerization induces a movement of a helical bundle that is formed by the thumb subdomain of PB1 and the N1 subdomain of PB2 (Fig. 3d, Supplementary Video 2) . This movement results in an opening of the binding site for the 3′ cRNA, which explains the absence of 3′ cRNA at this site in the dimeric structure. Furthermore, dimerization leads to rearrangements in the polymerase active site that could destabilize binding of the 3′ cRNA in the active site, which is consistent with the lack of density for the 3′ extremity of the 3′ cRNA in the dimer structure (Extended Data Fig. 5i) . Specifically, the visible residues that are closest to the tip of the priming loop (residues E638 and M656 of PB1) are moved away from the active site by approximately 7 Å, which presumably pulls the tip out by a similar distance (Extended Data Fig. 6i, Supplementary Video 3) . This movement of the priming loop, and the destabilized binding of the 3′ cRNA, could facilitate backtracking of the cRNA template during the initiation of vRNA synthesis, consistent with previous data that suggest that the priming loop is required during the realignment of the pppApGinitiating dinucleotide to the cRNA terminus 20, 21 . In further support of this model, we used cryo-EM to solve the structure of FluPol A bound to the vRNA promoter and capped RNA at a resolution of 3.0 Å (Extended Data Fig. 7a-f ). This structure, in which the flexible endonuclease domain of PA and C-terminal domains of PB2 are fully resolved, revealed the interaction of a fully resolved priming loop with the 3′ vRNA in the active site (Extended Data Fig. 7g ). The priming loop acts to buttress the template RNA, positioning it next the catalytic aspartates (residues D445 and D446 of PB1) to enable terminal initiation. This interaction is mediated by amino acid P651 of PB1 (positioned at the tip of the priming loop), which has previously been found to be critical for priming-loop function 21 . The observed buttressing of the template by the priming loop is consistent with our proposed model, in which template realignment for vRNA synthesis is triggered by polymerase dimerization (Extended Data Fig. 7h, Supplementary Video 4) .
To address the effect of Nb8205 on FluPol A function, we performed a mini-replicon assay and found that co-expression of Nb8205 severely inhibited the accumulation of all viral RNAs, whereas another nanobody (Nb8210)-which was also raised against FluPol A , but which does not affect FluPol A dimerization (Extended Data Fig. 4a-c) -had no significant effect (Fig. 4a) . Nb8205 had no effect on capped RNA-primed transcription or cRNA synthesis on a vRNA template, but strongly inhibited vRNA synthesis on a cRNA template in vitro (Fig. 4b-d) . Addition of Nb8205 to ApG dinucleotide-primed assays did not reduce activity, but did result in incorrectly initiated vRNA products on the cRNA template (Extended Data Fig. 8a-c) . Nb8205 inhibited vRNA accumulation at 16 to 32 h after infection in cells infected with influenza A/WSN/33 virus, and caused a significant reduction in virus titre; by contrast, Nb8210 had no (or a much smaller) effect (Fig. 4e, f) .
Collectively, these data show that FluPol A dimerization is required for the initiation of vRNA synthesis on the cRNA template during replication of the viral genome (Fig. 4g) . The dependency on dimerization of replication initiation on the cRNA template is consistent with previous observations that vRNA synthesis requires a trans-activating polymerase 8 . A requirement for trans-activation through polymerase dimerization provides a mechanism for tuning the amount of vRNA synthesized: vRNA production is initiated only when a sufficient level of newly made free polymerase is available in the cell. This could help to ensure that the virus does not produce vRNA that cannot be assembled into viral RNPs and that could, therefore, trigger an antiviral response through recognition by pathogen-recognition receptors (such as RIG-I) 22, 23 . It is interesting to note that we observe numerous avian-to-mammalian adaptive mutations at the dimer interface, which suggests that dimerization of FluPol A may be regulated in a host-specific manner (Extended Data Fig. 8d ). In conclusion, the complete, high-resolution structures of medically relevant human and avian FluPol A and the identification of sites that are involved in polymerase dimerization and cRNA promoter-binding will provide guidance for the development of antiviral drugs that target influenza.
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Methods
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Cells. Human embryonic kidney 293T (HEK293T) and Sf9 insect cells were sourced from the Cell Bank of the Sir William Dunn School of Pathology. HEK293T cells were maintained in Dulbecco's modified Eagle medium (DMEM) and Sf9 cells were maintained in Sf-900 II serum-free medium (Gibco). Cell lines have not been authenticated, but tested negative for mycoplasma contamination. Protein expression and purification. The three subunits of human influenza A/NT/60/1968 (H3N2) and avian influenza A/duck/Fujian/01/2002 (H5N1) virus polymerases were co-expressed in Sf9 cells from codon-optimized genes (GeneArt) cloned into a single baculovirus using the MultiBac system 24 . Mutagenesis of H3N2 FluPol A was carried out using the QuickChange Primer Design Program (Agilent). The influenza B/Panama/45/90 polymerase subunits were expressed as for FluPol A ; however, they were cloned into the biGBac system 25 before bacmid generation. Expression and purification of wild-type and mutant FluPol A and FluPol B were performed as previously described 8 with minor modifications. SEC was performed using 25 mM HEPES-NaOH, pH 7.5, 500 mM NaCl and 5% (v/v) glycerol (buffer A) on a Superdex 200 Increase 10/300 GL column (GE Healthcare). Pooled fractions from SEC were supplemented with 1 mM TCEP and the final product was concentrated to 3-5 mg ml −1 and used for crystallization, or flash-frozen in liquid nitrogen and stored at −80 °C until further use. All purification steps were performed at 4 °C. Generation, expression and purification of nanobodies. Nanobodies that target H5N1 FluPol A were generated following previously established protocols 26 .
The plasmid pMESy4 encoding C-terminal 6×His-tagged nanobodies were transformed into Escherichia coli strain WK6, grown in 2× YT medium containing 0.1% glucose, 2 mM MgCl 2 and 100 mg ml −1 ampicillin at 37 °C until the absorbance at 600 nm of the sample reached 0.7, and then induced with 1 mM IPTG and incubated overnight at 28 °C. Cells were collected, and the periplasmic fraction was extracted using the modified osmotic shock protocol. The periplasmic extract containing the nanobody was incubated with Ni-NTA agarose (Qiagen) for 1 h at room temperature. The beads were washed with 20 volumes of 50 mM K 2 HPO 4 :NaH 2 PO 4 , pH 7.0, 1 M NaCl, followed by 30 volumes of 50 mM K 2 HPO 4 :NaH 2 PO 4 , pH 6.0, 1 M NaCl. Nanobodies were eluted by the addition of 15 volumes of 50 mM sodium acetate, pH 4.6, 1 M NaCl. The eluate was neutralized by the addition of 5 volumes of 1 M Tris-HCl, pH 7.5 and concentrated using an Amicon Ultra centrifugal filter unit (Merck Millipore). Nanobodies were further purified on a Superdex 200 Increase 10/300 gel filtration column (GE Healthcare) in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl. Nanobodies were concentrated to 4 mg ml −1 , flash-frozen and stored at −20 °C. Crystallization, data collection and structure determination. Initial hits were found in sitting-drop vapour-diffusion experiments 27 at 20 °C in conditions with 0.8-1.2 M phosphate buffer. After optimization, H3N2 FluPol A protein was crystallized under the conditions of 0.9-1.2 M K 2 HPO 4 /NaH 2 PO 4 , pH 6.7, and H5N1 FluPol A under the conditions of 1 M K 2 HPO 4 /NaH 2 PO 4 , pH 6.9, 0.07% dichloromethane. Crystals appeared within 1-2 h and grew to full size after 3-4 days. Crystals were cryo-protected by soaking for 10-30 s in 25% (v/v) glycerol or 20% (v/v) ethylene glycol in crystallization buffer, before flash-freezing in liquid nitrogen. H3N2 FluPol A was co-crystallized with Nb8205, added to FluPol A in a 1.5-fold molar excess, using the same conditions as for apo FluPol A . Additional nanobody was added during crystal stabilization and freezing. Diffraction data were collected at −173 °C on beamlines I03 (wavelength 0.9159 Å) and I24 (wavelength 0.9686 Å) (for H3N2 FluPol A ) and I04 (wavelength 0.9795 Å) (for H5N1 FluPol A and H3N2 FluPol A + Nb8205), at the Diamond Light Source. Data were processed using XDS 28 and STARANISO 29 , using an anisotropic cut-off and the mean I/σ(I) value of 1.20 to determine the diffraction-limit surface. The structure of H5N1 FluPol A was solved by molecular replacement using Phaser-MR 30 as implemented in PHENIX 31 , and a search model of the FluPol C structure 15 (RCSB Protein Data Bank identifier (PDB) 5D98) with the PB2 627 domain deleted from the model. Positions of individual 627 domains were obtained by a second round of molecular replacement. After rigid-body refinement, the structure was rebuilt with Coot 32 and refined with PHENIX 31 and autoBUSTER 33 until R-factor values converged. Translation-libration-screw parameters and fourfold torsion-angle noncrystallographic symmetry restraints were also applied in refinement. The structure of H3N2 FluPol A was solved by molecular replacement using the structure of H5N1 FluPol A (this study) as the search model, and refined in the same way. To determine the structure of human FluPol A in complex with Nb8205, chain N of PDB 3SN6 34 was used as a search model for the nanobody. In the final H3N2 FluPol A model, 93.31% residues are in the most-favoured regions of the Ramachandran plot and 0.09% are in the disallowed regions (90.93% and 0.08% for H5N1 FluPol A model and 92.65% and 0% for H3N2 FluPol A + Nb8205 model, respectively). Cryo-EM sample preparation. Purified dimer fraction of H3N2 FluPol A was mixed with a 1.2-fold molar excess of 5′ and 3′ cRNA promoters (5′ cRNA, 5′-pAGCAAAAGCAGGCC-3′; 3′ cRNA, 5′-GGCCUUGUUUCUACU-3′) or vRNA promoters (5′ vRNA, 5′-pAGUAGAAACAAGGCC-3′; 3′ vRNA, 5′-GGCCUGCUUUUGCU-3′) and-if stated-a 2.5-fold molar excess of purified Nb8205 to prepare the cRNA-bound FluPol A -nanobody complex. The samples were injected into a Superdex 200 Increase 10/300 GL column (GE Healthcare) running in 25 mM HEPES-NaOH, pH 7.5, 500 mM NaCl. The fractions of interest were concentrated, and protein surface charges were neutralized by adding 0.001% glutaraldehyde for 20 min on ice, to minimize preferential orientation of particles. After quenching the reaction by adding Tris-HCl, pH 8.0 to a final concentration of 100 mM, the sample was re-injected into a Superdex 200 Increase 10/300 GL column (GE Healthcare) running in 25 mM HEPES-NaOH, pH 7.5, 500 mM NaCl. The fractions of interest were concentrated to 1 mg ml −1 and diluted threefold into 25 mM HEPES-NaOH, pH 7.5, 37.5 mM NaSCN, 0.0075% (v/v) Tween 20 before grid preparation. A volume of 3.5 μl of cRNA-bound FluPol A at a concentration of 0.35 mg ml -1 was placed on glow-discharged carbon-coated (40-nm film) copper C-flat grids (Protochips) with 2-μm holes and 1.0-μm spacing, before blotting for 3.5 s and flash-freezing in liquid ethane. The purified fraction of FluPol B was mixed with a 1.2-fold molar excess of 5′ and 3′ cRNA promoters (5′ cRNA, 5′-pAGCAAAAGCAGGCC-3′; 3′ cRNA, 5′-GGCCUUGUUUCUA CU-3′), and the sample was processed as described for FluPol A and concentrated to 0.35 mg ml −1 . A volume of 3.5 μl of cRNA-bound FluPol B was used to prepare grids as described above. All grids were prepared using a Vitrobot mark IV (FEI) at 95-100% humidity. Cryo-EM image collection and processing. Cryo-EM data were collected on a 300-kV Titan Krios microscope (Thermo Fisher Scientific) fitted with a GIF Quantum energy filter (Gatan) at either the Division of Structural Biology (Strubi) or Electron Bio-Imaging Centre (eBIC). For the FluPol A datasets, a volta phase plate (Thermo Fisher Scientific) was used. Micrographs were recorded in counting mode using a K2 Summit (Gatan) direct electron detector (or K3 for the FluPol AvRNA data set). For sample-specific data collection parameters, see Extended Data Table 2 . Video data were processed using MotionCor2-1.1.0 35 , with a five-by-five patch-based alignment, keeping all the frames and dose-weighting up to the total exposure. The contrast transfer function (CTF) and additional phase-shift of fulldose, non-weighted micrographs was estimated using Gctf-v.1.18 or Gctf-v.1.06 36 for the FluPol B dataset. Poor-quality images were discarded after manual inspection. For cRNA-bound dimeric FluPol A , 56,070 particles were manually picked from the dose-weighted micrographs using the RELION 3.0 37 manual picking tool, then extracted in a 250-pixel box and subjected to 1 round of two-dimensional (2D) classification resulting in 16 classes with 43,316 selected particles. Threedimensional (3D) classification with alignment into three different classes was performed. Two of the classes, containing a total number of 36,913 particles, were selected and refined to 4.2 Å with C 2 symmetry. Bayesian polishing and per particle CTF refinement were performed in RELION 3.0, which improved map resolution to up to 4.07 Å. The same particles were also refined without symmetry, resulting in a map with a resolution of 4.34 Å. Local resolution estimation and sharpening was performed by the RELION sharpening tool, using a −100 Å 2 and −80 Å 2 B-factor, respectively. For the cRNA-bound FluPol A -Nb8205 complex, a first set of 406,945 particles was automatically picked with the template picker implemented in cryoSPARC v2.5 38 , using 2D classes from cRNA-bound FluPol A as a template, and then 2D-classified. A final set of 34,162 particles, containing only the dimeric form of the complex, was exported to RELION 3.0 in a 250-pixel box, and the monomeric classes were used as template for another round of automatic picking. From an initial set of 505,860 particles, 216,066 particles (containing only the monomeric form) were selected after 2D classification and exported into RELION 3.0 in a 200-pixel box. Both the dimer and monomer datasets were refined individually using C 1 symmetry to a resolution at 4.38 Å and 4.1 Å, respectively. Bayesian polishing and per particle CTF refinement were performed in RELION 3.0, which improved map resolution to up to 4.15 Å and 3.79 Å, respectively. For the vRNAbound FluPol A , a first set of 2,210,168 particles was automatically picked with the template picker implemented in cryoSPARC v.2.5 38 , using 2D classes from cRNA-bound FluPol A as a template, and then 2D-classified. A final set of 432,160 particles, containing only the monomeric form of the complex, was exported to RELION 3.0 in a 250-pixel box. The data were refined to a resolution of 3.3 Å using C 1 symmetry. Bayesian polishing and per particle CTF refinement were performed in RELION 3.0, which improved map resolution to up to 2.9 Å. A final iteration of 3D classification was performed in RELION 3.0, which gave a final map at a resolution of 3.01 Å with a final set of 170,144 particles. For cRNA-bound FluPol B , a first set of 1,012,085 particles was automatically picked with the template picker implemented in cryoSPARC v.2.5 38 , using 2D classes of the cRNA-bound FluPol ANb8205 complex as a template. After 2D classification, the best views were selected for another round of automatic picking. From an initial set of 324,395 particles, 41,549 particles were selected after 3D classification and exported to RELION 3.0 in a 200-pixel box. The data were refined to a resolution of 4.18 Å using C 1 symmetry. The structures were modelled by first fitting an initial model into the locally Letter reSeArCH sharpened map using UCSF Chimera 39 . One cycle of rigid-body real-space refinement, followed by manual adjustment in Coot 40 , was performed to correctly position the Cα chain into the density. Finally, cycles of PHENIX 31 real-space refinement and manual building in Coot 40 were used to improve model geometry. Map-to-model comparison in PHENIX mtriage validated that no over-fitting was present in the structures. Model geometry was validated for all models using MolProbity 41 . All map and model statistics are detailed in Extended Data Table 2 . Analytical SEC. Analytical SEC experiments were performed on a Superdex 200 Increase 10/300 GL column (GE Healthcare) using buffer A. Wild-type or mutant FluPol A was loaded via a 100-μl sample loop at a concentration of 10 μM. For investigating the effect of nanobodies, the nanobody was added to FluPol A in a 1.5-fold molar excess and incubated on ice for 1 h before injection. SEC-SAXS. SEC-SAXS experiments were performed on beamline B21 at the Diamond Light Source. In brief, 45 μl of purified FluPol A at a concentration of 12 μM was injected into a Shodex KW-403 size-exclusion column under a flow rate of 0.16 ml min −1 at 20 °C in buffer A. Data were collected using continuous three-second exposures. The data were buffer-subtracted, scaled, merged and analysed using the ScÅtter 3.0 software (http://www.bioisis.net/scatter). The molecular mass of each individual frame was estimated from DATASW 42 . SEC coupled to multi-angle light scattering. SEC coupled to multi-angle light scattering (SEC-MALS) experiments were performed on beamline B21 at the Diamond Light Source. In brief, 45 μl of purified FluPol A at a concentration of 4 μM was injected into a Shodex KW-403 size-exclusion column under a flow rate of 0.16 ml min −1 at 20 °C in buffer A in the absence of glycerol. An 18-angle multi-angle light-scattering instrument (DAWN HELEOS, WYATT) was used to collect light scattering data and the data were processed with ASTRA (WYATT). Plasmids. The plasmids pcDNA-PB1, pcDNA-PB1a, pcDNA-PB1-Flag, pcDNA-PB1-TAP (PB1 fused to a C-terminal tandem affinity purification (TAP) tag that consists of a calmodulin binding domain (CBD), a tobacco etch virus (TEV) protease cleavage site, and two copies of protein A), pcDNA-PB2, pcDNA-PB2-TAP, pcDNA-PA, pcDNA-PA(D108A), pcDNA-NP and pPOLI-NA have previously been described 12, [43] [44] [45] [46] [47] . The plasmids pcDNA-PB2(71-73A), pcDNA-PA(351-353A), pcDNA-PA(356-358A) and pcDNA-PA(352-356A), which encode mutant PB2 and PA subunits of polymerase, were generated from pcDNA-PB2 and pcD-NA-PA using site-directed PCR mutagenesis. The plasmids pcDNA-Nb8205 and pcDNA-Nb8210 (for expressing nanobodies Nb8205 and Nb8210 in mammalian cells) were generated by PCR amplification, using pMESy4 plasmids as templates and cloning into pcDNA3A. FluPol A dimerization assay. Dimerization of FluPol A in HEK293T cells was assessed as previously described 48 . Protein complexes were analysed by SDS-PAGE and silver-staining using SilverXpress (Invitrogen) and bands of PB1-Flag and PB1-CBD were quantified in ImageJ 49 . RNP reconstitution assay and primer extension analysis. Approximately 0.2 × 10 6 HEK293T cells were transfected with 0.2 μg of each pcDNA plasmid encoding PB1, PB2, PA and NP, and pPOLI plasmid encoding the neuraminidase (NA) vRNA segment, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Plasmids that encode mutant proteins or nanobodies were included as indicated. For the complementation assay with a transcriptiondeficient but replication-competent PA(D108A) polymerase, equal amounts of pcDNA-PA(D108A) and pcDNA-PA(356-358A) were co-transfected as previously described 13, 48 . Cells were collected 20 h after transfection, and total cellular RNA was extracted using TRI reagent (Sigma) according to the manufacturer's instructions. vRNA levels were analysed using primer extension as previously described 50 . In brief, RNA was reverse-transcribed using 32 P-labelled primers specific to positive-and negative-sense vRNAs, with a primer specific to cellular 5S rRNA as a loading control. Transcripts were separated by 6% denaturing PAGE, and visualized by phosphor-imaging on an FLA-5000 scanner (Fuji). Analysis was carried out using ImageJ 49 and Prism 7 (GraphPad). vRNA levels were normalized to the 5S rRNA loading control. Virus growth analysis. Approximately 10 6 HEK293T cells were transfected with 5 μg of pcDNA plasmid encoding Nb8205, Nb8210 or an empty pcDNA3 vector, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Subsequently, 24 h after transfection, cells were infected with influenza A/WSN/33 virus at a multiplicity of infection of 0.1. Medium was collected 12, 24, 36 and 48 h after infection, and virus titres were determined by plaque assay. At each time point, total cellular RNA was also extracted using TRI reagent (Sigma) and vRNA levels were analysed by primer extension 50 . In vitro transcription assays. In vitro transcription assays were carried out as previously described 21 . In brief, a cap-1 structure was added to a synthetic 11-nucleotide RNA (5′-ppGAAUACUCAAG-3′) (ChemGenes) by mixing 1 μM of RNA with 0.25 μM [α-
32 P]GTP (3,000 Ci mmol −1 ; Perkin-Elmer), 0.8 mM S-adenosylmethionine, 0.5 U μl −1 vaccinia virus capping enzyme (NEB) and 2.5 U μl −1 2′-O-methyltransferase (NEB) in a 20-μl reaction at 37 °C for 1 h. The product was isolated by 16% denaturing PAGE, excised, eluted overnight in dH 2 O and desalted using NAP-10 columns (GE Healthcare). Transcription reactions were performed using about 1,500 c.p.m. capped RNA primer in a 3-μl reaction mixture containing 1 mM ATP, 0.5 mM CTP, 0.5 mM UTP, 0.1 μM GTP, 5 mM MgCl 2 , 1 mM DTT, 2 U μl −1 RNasin, 0.5 μM 5′ vRNA promoter, 0.5 μM 3′ vRNA promoter, 70 ng Nb8205 (if indicated) and 100 ng H3N2 FluPol A . Reactions were incubated for 10 min at 30 °C and stopped by the addition of an equal volume of 80% formamide, 1 mM EDTA, and bromophenol blue and xylene cyanol dyes, followed by incubation at 95 °C for 3 min. Products were resolved by 20% denaturing PAGE and visualized by phosphor-imaging on an FLA-5000 scanner (Fuji). Analysis was carried out using ImageJ 49 and Prism 7 (GraphPad). In vitro replication assays. Primer-independent and ApG extension assays were carried out as previously described 21 . In brief, 3-μl reaction mixtures containing 1 mM ATP, 0.5 mM CTP, 0.5 mM UTP (if indicated), 0.1 μM GTP, 0.05 μM [α- ; Perkin-Elmer), 0.25 mM ApG (if indicated), 5 mM MgCl 2 , 1 mM DTT, 2 U μl −1 RNasin, 0.5 μM 5′ vRNA or cRNA promoter, 0.5 μM 3′ vRNA or cRNA promoter, 70 ng Nb8205 (if indicated) and 10-100 ng H3N2 FluPol A were incubated at 37 °C for 4 h. Where PB1a active-site-mutant polymerase was added, the concentrations of 5′ and 3′ cRNA promoters were adjusted accordingly, to maintain a constant molar ratio of promoter to polymerase. Reactions were stopped by addition of an equal volume of 80% formamide, 1 mM EDTA, and bromophenol blue and xylene cyanol dyes, followed by incubation at 95 °C for 3 min. Products were resolved by 20% denaturing PAGE and visualized by phosphor-imaging on an FLA-5000 scanner (Fuji). Analysis was carried out using ImageJ 49 and Prism 7 (GraphPad). Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. Data are mean ± s.e.m. n = 3 independent transfections. One-way ANOVA. P < 0.05 is considered significant. c, Effect of mutations designed to destabilize PB2, and PA loops, at the FluPol A dimer interface on FluPol A activity in a viral RNP reconstitution assay. Data are mean ± s.e.m. n = 3 independent transfections. Two-way ANOVA. P < 0.05 is considered significant. d, e, Effect of PA(352-356A) mutation on in vitro ApG-primer replication by FluPol A on a vRNA (d) and cRNA (e) template. f, Effect of an active-site polymerase mutant (PB1a) on in vitro ApGprimer replication by FluPol A on a cRNA template. Data are mean ± s.e.m. n = 4 independent reactions. g, Omitting UTP from in vitro ApG-primer replication by FluPol A on a cRNA template affects the synthesis of the 15-nucleotide, full-length vRNA but not of the 12-nucleotide, short vRNA, which indicates that the 12-nucleotide product is derived from internal initiation by the ApG dinucleotide at positions 4 and 5 of the cRNA template. The position in the template at which UTP is required is indicated in red. Representative data from n = 2 independent reactions. For gel source data, see Supplementary Fig. 2 . Curves are shown for phase-randomization, unmasked, masked and phase-randomization-corrected masked maps. d, A 3D reconstruction, locally filtered and coloured according to RELION local resolution. e, Angular distribution of particle projections with the cryo-EM map shown in grey. f, Cryo-EM density of the PA loop 352-356 at the dimer interface. g, Cryo-EM map of cRNA-bound FluPol A dimer refined without symmetry imposed (C 1 ), which reveals an extra density (green) located next to the 3′ end of the 5′ cRNA close to the template entry channel. h, Close-up views highlighting extra density in the cryo-EM map (dark green) with the 3′ vRNA strand from the superimposed FluPol B structure 51 (PDB 5MSG, light green) inserting into the polymerase active site. Localization of the 3′ vRNA shows that bases are positioned in the extra density, facing the density that corresponds to the 3′ end of the 5′ cRNA. This suggests the presence of a promoter RNA duplex region, as observed in the vRNA-bound FluPol B structure 51 . The extra density is consistent with the presence of a 3′ cRNA in one of the heterotrimers of the cRNAbound FluPol A dimer, oriented towards the polymerase active site. 
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